Tiago Fauth
Stock Analyst at Wells Fargo
(2.36)
# 2,567
Out of 5,149 analysts
152
Total ratings
43.97%
Success rate
-0.63%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $171 → $217 | $147.00 | +47.62% | 9 | Oct 31, 2025 | |
| WVE Wave Life Sciences | Maintains: Overweight | $21 → $18 | $13.44 | +33.93% | 4 | Sep 4, 2025 | |
| UTHR United Therapeutics | Maintains: Equal-Weight | $295 → $414 | $498.65 | -16.98% | 7 | Sep 3, 2025 | |
| MNKD MannKind | Maintains: Overweight | $9 → $10 | $2.93 | +241.88% | 2 | Sep 3, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $79 → $73 | $64.39 | +13.37% | 5 | Aug 20, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $25 → $31 | $31.78 | -2.45% | 3 | Aug 13, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $333 → $395 | $318.65 | +23.96% | 7 | Aug 1, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $22.07 | +194.52% | 8 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $64.53 | +17.77% | 1 | Jun 30, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $5.58 | +25.45% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $101 | $24.40 | +314.02% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.25 | +140.00% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $13.40 | +94.03% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $14.34 | +18.55% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $64.36 | +16.53% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $14.00 | +342.86% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $239.22 | -62.80% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $29.32 | +73.94% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $58.53 | +105.02% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $26.71 | -85.02% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.57 | +444.75% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $300 | $55.83 | +437.35% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $8.50 | +205.88% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.71 | +654.72% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $20.16 | +301.79% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.19 | +4,224.32% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.43 | +879.02% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $2.07 | +1,542.51% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $28.08 | +434.19% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $40.74 | -28.82% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.73 | +651.45% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.04 | +537.25% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.91 | +119.20% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $748.72 | -54.59% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $377.00 | -31.30% | 1 | Apr 28, 2021 |
Insmed
Oct 31, 2025
Maintains: Overweight
Price Target: $171 → $217
Current: $147.00
Upside: +47.62%
Wave Life Sciences
Sep 4, 2025
Maintains: Overweight
Price Target: $21 → $18
Current: $13.44
Upside: +33.93%
United Therapeutics
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $295 → $414
Current: $498.65
Upside: -16.98%
MannKind
Sep 3, 2025
Maintains: Overweight
Price Target: $9 → $10
Current: $2.93
Upside: +241.88%
PTC Therapeutics
Aug 20, 2025
Maintains: Overweight
Price Target: $79 → $73
Current: $64.39
Upside: +13.37%
Liquidia
Aug 13, 2025
Maintains: Overweight
Price Target: $25 → $31
Current: $31.78
Upside: -2.45%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $333 → $395
Current: $318.65
Upside: +23.96%
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $22.07
Upside: +194.52%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $64.53
Upside: +17.77%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $5.58
Upside: +25.45%
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $24.40
Upside: +314.02%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.25
Upside: +140.00%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $13.40
Upside: +94.03%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $14.34
Upside: +18.55%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $64.36
Upside: +16.53%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $14.00
Upside: +342.86%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $239.22
Upside: -62.80%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $29.32
Upside: +73.94%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $58.53
Upside: +105.02%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $26.71
Upside: -85.02%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.57
Upside: +444.75%
May 16, 2023
Reiterates: Outperform
Price Target: $300
Current: $55.83
Upside: +437.35%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $8.50
Upside: +205.88%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.71
Upside: +654.72%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $20.16
Upside: +301.79%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.19
Upside: +4,224.32%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.43
Upside: +879.02%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $2.07
Upside: +1,542.51%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $28.08
Upside: +434.19%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $40.74
Upside: -28.82%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.73
Upside: +651.45%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.04
Upside: +537.25%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.91
Upside: +119.20%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $748.72
Upside: -54.59%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $377.00
Upside: -31.30%